References
- Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001. 44(12):2862–9. Available from http://www.ncbi.nlm.nih.gov/pubmed/11762947. Last accessed 11 February 2015.
- Chan JW, Castellanos A. Infliximab and anterior optic neuropathy: Case report and review of the literature. Graefe’s Arch Clin Exp Ophthalmol 2010;248:283–7.
- Ten Tusscher MP, Jacobs PJ, Busch MJ, de Graaf L, Diemont WL. Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ 2003. 326(7389):579. Available from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=151521&tool=pmcentrez&rendertype=abstract. Last accessed 26 January 2015.
- Simsek I, Erdem H, Pay S, Sobaci G, Dinc A. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2007;66:1255–8.
- Winthrop KL, Chen L, Fraunfelder FW, Ku JH, Varley CD, Suhler E, et al. Initiation of anti-TNF therapy and the risk of optic neuritis: From the safety assessment of biologic ThERapy (SABER) study. Am J Ophthalmol 2013. 155(1):183–9. Available from http://dx.doi.org/10.1016/j.ajo.2012.06.023.
- Cruz Fernández-Espartero M, Pérez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, Gómez-Reino JJ, et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 2011. 41(3):524–33. Available from http://dx.doi.org/10.1016/j.semarthrit.2011.05.003.
- Rodriguez M, Siva A, Cross SA, O’Brien PC, Kurland LT. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 1995;45:244–50.
- The optic neuritis study group. Multiple sclerosis risk after optic neuritis. Arch Neurol 2008;65:727–32.
- Tristano AG. Neurological adverse events associated with anti-tumor necrosis factor alpha treatment. J Neurol 2010;257:1421–31.
- Sedwick LA, Klingele TG, Burde RM, Behrens MM. Optic neuritis in inflammatory bowel disease. J Clin Neuroophthalmol 1984. 4(1):3–6. Available from http://www.ncbi.nlm.nih.gov/pubmed/6233306. [ Last accessed 11 February 2015].
- Steenholdt C, Svenson M, Bendtzen K, Thomsen OA, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: Aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011;34:51–8.